Guidotti Luca Professore ordinarioMedicinaMED/04 Patologia generale

Biografia

Pubblicazioni

English version

Biografia

Breve narrativa

Il prof. Luca G. Guidotti è un patologo sperimentale di fama internazionale. Il Prof. Guidotti ha lavorato più di venti anni presso lo Scripps Research Institute di La Jolla in California e attualmente ricopre la carica di Vice-Direttore Scientifico dell’ IRCCS Ospedale San Raffaele (OSR) di Milano. Ha pubblicato sulle più prestigiose riviste scientifiche internazionali come Cell, Nature, Nature Medicine o Science ed è risultato vincitore di prestigiosi finanziamenti da parte del National Institute of Health (NIH) americano e l’ European Research Council (ERC). Presso l’NIH e ERC, il Prof. Guidotti ha servito e continua a servire come revisore per la ripartizione dei finanziamenti internazionali alla ricerca biomedica.

http://scholar.google.it/citations?user=qkFz9wYAAAAJ&hl=it

Cariche attuali

2017-oggi  Professore Ordinario di Patologia Generale, Università Vita-Salute San Raffaele, Milano.

2013-oggi  Vice-Direttore Scientifico, IRCCS Ospedale San Raffaele (OSR), Milano.

2005-oggi  Responsabile, Unità di Ricerca “Immunopatologia”, OSR, Milano.

2005-oggi  Professore Aggiunto di Patologia Sperimentale, The Scripps Research Institute (TSRI),

La Jolla, California.

Cariche precedenti

2012-2013  Direttore, Divisione di Immunologia, Trapianti e Malattie Infettive, OSR, Milano.

1999-2005  Professore Associato di Patologia Sperimentale, TSRI, La Jolla, California, USA.

1995-1999  Ricercatore (Assistant Professor) di Patologia Sperimentale, TSRI, La Jolla, California.

1992-1995  Ricercatore (Assistant Professor) in Patologia Generale, Facoltà di Medicina e Chirurgia, Università di Parma, Parma.

1991-1994  Borsista Post-Dottorato, TSRI, La Jolla, California, USA.

 

Premi e Memberships

2010-2016  Vincitore, Advanced Grant dell’European Research Council (ERC): “Imaging liver immunopathology by intravital microscopy.

2008-oggi    Membro, Istituto Eureka per la Medicina Traslazionale.

2004            Membro Onorario, Società di Medicina e Scienze Naturali dell’Università di Parma.

2003                    Membro, NIH/NIAID Advisory Panel for the Study of Liver Diseases.

2001                    Medaglia d’oro per “Excellence in Antiviral Research”, Tokyo, Giappone.

1998-oggi    Membro, Comitato Organizzatore del Congresso Annuale Internazionale su “Hepatitis B Viruses”.

1996-2014   Vincitore, Grant AI40696 del NIH americano: “Regulation of HBV replication by the  immune system”.

Attività di revisione per finanziamenti alla ricerca biomedica

2013-oggi    Revisore e Membro Permanente del Pannello LS6 “Immunity and Infection”, ERC Starting Grants (StG), Bruxelles.

2012            Revisore, NIH Special Emphasis Panel ZRG1 IDM-B (03), Washington, D.C.

2011-2012   Revisore, The Research Foundation Flanders (FWO), Bruxelles.

2010                     Revisore, Recovery act limited competition: NIH Directors’ opportunity for research in 5 thematic areas (RC4), Washington, D.C.

2009            Chairman, European Congress of Immunology (ECI), Berlino.

2008-2010   Revisore, BMRC & NMRC Grants, Singapore.

2008            Revisore, NIH RFA-ZDK1 “Hepatitis B Clinical Research Network”, Washington, D.C.

2007-2014   Revisore Esterno, ERC StG and Consolidator Grants, 2007, 2010 and 2014, 2017.

2002-2003   Revisore, The Wellcome Trust, UK, Project Grants, Londra.

2002            Revisore, RFP-NIH-NIAID “Drug Development for Opportunistic Infections: Hepatitis C” Study Section ZAI1-GPJ-A-C1, Washington, D.C.

2001            Revisore, NIH Special Study Section (ZRG MBC-2), Washington, D.C.

2000-2001   Revisore, NIH Virology (VR) B, Study Section, Washington, D.C.

1998-2000   Revisore, NIH General Medicine (GM) 2, Study Section Washington, D.C.

Board editoriali

2015-oggi     Current Opinion of Virology 

Attività di revisione per articoli scientifici 

1995-oggi     Revisore per: Cell, Nature, Nature Medicine, Science, Science Immunology, Proc. Nat’l Acad. Sci., USA, The Lancet, Journal of Experimental Medicine, Journal of Clinical Investigation, PloS Pathogens, American Journal of Pathology, Journal of Immunology, Journal of Virology, Virology, Journal of Infectious Diseases, Human Gene Therapy, Hepatology, Journal of Hepatology.

 Organizzazione di meeting scientifici

2017             Co-Organizzatore della Nature Conference on “Regeneration”, OSR, Milano.

1998             Organizzatore del meeting internazionale: “The Molecular Biology of Hepatitis B Viruses”, Università della California di San Diego (UCSD).

 Attività didattiche

2008-2017    Professore a Contratto di Patologia Generale, Università Vita-Salute San Raffaele, Milano.

Incarichi istituzionali

2010-oggi      Membro, Organismo preposto al benessere degli animali (OPBA), OSR, Milano.

2013-oggi      Membro, Comitato per il Conflitto Finanziario di OSR, Milano.

2013-oggi      Membro, Comitato Etico per la Sperimentazione Clinica, OSR, Milano.

2013-oggi      Membro, Comitato Brevetti, OSR, Milano.

Appartenenza a Società Scientifiche

Membro di:    Henry Kunkel Society, American Association of Immunology, American Society for Microbiology, Italian Society of Clinical Immunology and Allergology (SIICA)

Consigli di amministrazione (CDA) e Advisory Boards

2004-oggi      Co-fondatore e membro del CDA di Capitalife, Reno, Nevada, USA.

2013-oggi      Membro, Gilead Sciences “HBV CURE Advisory Board”, Foster City, Califorina.

2015-oggi      Membro and Vice-Portavoce, Research4life (http://www.research4life.it), Milano.

2017-oggi      Membro, International Coalition to Eliminate Hepatitis B virus (ICE-HBV), Melbourne.

Pubblicazioni

 

 

  • 1.         Jiménez de Oya N, M. De Giovann, J. Fioravanti, R. Übelhart, P. Di Lucia, A. Fiocchi, S. Iacovelli, D.G. Efremov, F. Caligaris-Cappio, H. Jumaa, P. Ghia, L.G. Guidotti and M. Iannacone. Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens. EMBO Mol Med. 2017. doi: 10.15252/emmm.201707732.
  • 2.         Sammicheli S., M. Kuka, P. Di Lucia, N. Jimenez de Oya, M. De Giovanni, J. Fioravanti, C. Cristofani, C.G. Maganuco, B. Fallet, L. Ganzer, L. Sironi, M. Mainetti, R. Ostuni, K. Larimore, P.D. Greenberg, J.C. de la Torre, L.G. Guidotti and M. Iannacone. Inflammatory monocytes hinder antiviral B cell responses. Science Immunology, 2016, doi: 10.1126/sciimmunol.aah6789.
  • 3.         M. Catarinella, A. Monestiroli A, G. Escobar, A. Fiocchi, N.L. Tran, R. Aiolfi, P. Marra, A. Esposito, F. Cipriani, L. Aldrighetti, M. Iannacone, L. Naldini, L.G. Guidotti and G. Sitia. IFNα gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment. EMBO Mol Med. 14:155-170, 2016.
  • 4.         Guidotti L.G., D. Inverso, L. Sironi, P. Di Lucia, J. Fioravanti, L. Ganzer, A. Fiocchi, M. Vacca, R. Aiolfi, S. Sammicheli, M. Mainetti, T. Cataudella, A. Raimondi, G. Gonzalez-Aseguinolaza, U. Protzer, F.V. Chisari, Z.M. Ruggeri, M. Isogawa, G. Sitia, and M. Iannacone. Immunosurveillance of the Liver by Intravascular Effector CD8+ T cells. Cell 3:486-500, 2015.
  • 5.         Sitia G., R. Aiolfi , P. Di Lucia, M. Mainetti, A. Fiocchi, F. Mingozzi, A. Esposito, Z.M. Ruggeri, F.V. Chisari, M. Iannacone and L.G. Guidotti. Anti-platelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc. Nat’l Acad. Sci, USA Plus 109(32):E2165-E2172, 2012.
  • 6.         Sitia G., M. Iannacone, R. Aiolfi, M. Isogawa, N. van Rooijen, C. Scozzesi, M.E. Bianchi, U.H. von Andrian, F.V. Chisari and L.G. Guidotti. Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. Plos Pathogens 2011 Jun;7(6):e1002061. Epub 2011 Jun 2.
  • 7.         Iannacone, M., E.A. Moseman, E. Tonti, L. Bosurgi, T. Junt, S.E. Henrickson, S.P. Whelan, L.G. Guidotti and U.H. von Andrian. Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. Nature 465:1079-83, 2010.
  • 8.         Iannacone, M., G. Sitia, M. Isogawa, J.K. Whitmire, P. Marchese, F.V. Chisari, Z.M. Ruggeri and L.G. Guidotti. Platelets prevent IFNα-/ß-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc. Nat’l Acad. Sci, USA105:629-634, 2008.
  • 9.         Sitia G, M. Iannacone, Su. Müller, M.E Bianchi and L.G Guidotti. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease. J. Leukoc. Biol. 81:100-107, 2007.
  • 10.       Iannacone, M., G. Sitia G., M. Isogawa, P. Marchese, M.G. Castro, P.R. Lowenstein, F.V. Chisari, Z.M. Ruggeri and L.G. Guidotti. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat. Med. 11:1167-1169, 2005.
  • 11.       Sitia G., M. Isogawa, M. Iannacone, I.L. Campbell, F.V. Chisari and L.G. Guidotti. MMPs are required for recruitment of antigen non-specific mononuclear cells into the liver by CTLs. J. Clinical Investigation. 113:1158-1167, 2004.
  • 12.       Sitia G., M. Isogawa, K. Kakimi, S.F. Wieland, F.V. Chisari and L.G. Guidotti. Depletion of neutrophils blocks the recruitment of antigen non-specific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc. Nat’l Acad. Sci, USA  99:13717-13722, 2002.
  • 13.       Kakimi, K., T. E. Lane, S. F. Wieland, V.C. Asensio, I. L. Campbell, F.V. Chisari and L.G. Guidotti. Blocking chemokine responsive to {gamma}–2/interferon (IFN)-{gamma} inducible protein and monokine induced by IFN-{gamma} activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus–specific cytotoxic T lymphocytes J. Exp. Med. 194:1755-1766, 2001.
  • 14.       McClary, H., R. Koch, F.V. Chisari and L.G. Guidotti. Inhibition of hepatitis B virus replication during Schistosoma mansoni infection in transgenic mice. J. Exp. Med. 192: 289-294, 2000.
  • 15.       Guidotti, L.G., H. McClary, J. Moorhead and F.V. Chisari. Nitric oxide inhibits HBV replication in the liver of transgenic mice. J. Exp. Med. 191:1247-1252, 2000.
  • 16.       McClary, H., R. Koch, F.V. Chisari and L.G. Guidotti. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J. Virol. 74:2255-2264, 2000.
  • 17.       von Herrath, M., B. Coon, D. Homann T. Wolf and L.G. Guidotti. Thymic tolerance to only one viral protein reduces lymphocytic choriomeningitis virus-induced immunopathology and increases survival in perforin-deficient mice. J. Virol. 73:5918-5925, 1999.
  • 18.       Guidotti, L.G., P. Borrow, A. Brown, H. McClary, R. Koch and F.V. Chisari. Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte. J. Exp. Med. 189:1555-1564, 1999.
  • 19.       Guidotti, L.G., R. Rochford, J. Chung, M. Shapiro, R. Purcell and F.V. Chisari. Viral clearance without destruction of infected cells in acute HBV infection. Science 284:825-829, 1999.
  • 20.       Nakamoto, Y., L.G. Guidotti, C. Kuhlen, P. Fowler and F.V. Chisari. Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 188:341-350, 1998.
  • 21.       Guidotti, L.G., B. Matzke and F.V. Chisari. HBV replication is cell cycle independent during liver regeneration in transgenic mice. J. Virol. 71:4804-4808, 1997.
  • 22.       Guidotti, L.G., P. Borrow, M.V. Hobbs, B. Matzke, I. Gresser, M.B.A. Oldstone and F.V. Chisari. Viral cross talk: Intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc. Nat’l Acad. Sci, USA, 93:4589-4594, 1996.
  • 23.       Guidotti, L.G., T. Ishikawa, M.V. Hobbs, B. Matzke, R. Schreiber and F.V. Chisari. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25-36, 1996.
  • 24.       Guidotti, L.G., B. Matzke, H. Schaller and F.V. Chisari. High-level hepatitis B virus replication in transgenic mice. J. Virol. 69:6158-6169, 1995.
  • 25.       Guidotti, L.G., V. Martinez, Y.T. Loh, C.E. Rogler and F.V. Chisari. Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice. J. Virol. 68:5469-5475, 1994.
  • 26.       Guidotti, L.G., K. Ando, M.V. Hobbs, T. Ishikawa, L. Runkel, R.D. Schreiber and F.V. Chisari. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Nat’l Acad. Sci, USA 91:3764-3768, 1994.
  • 27.       Guidotti, L.G., S. Guilhot and F.V. Chisari. Interleukin-2 and interferon alpha/beta down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor dependent and independent pathways. J. Virol. 68:1265-1270, 1994.

 

Peer-reviewed reviews

  • 1.         Guidotti L.G., M. Isogawa and F.V. Chisari. Host-virus interactions in hepatitis B virus infection. Current Opinion Immunology, 36:61-66, 2015.
  • 2.         Sitia G., M. Iannacone and L.G. Guidotti. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol. 59:1135-1138, 2013.
  • 3.         Guidotti, L.G. and F.V. Chisari. Immunobiology and pathogenesis of viral hepatitis. Review. Annu. Rev. Pathology. 1:23-61, 2006.
  • 4.         Guidotti, L.G. and F.V. Chisari. Noncytolytic control of viral infections by the innate and adaptive immune response. Review. Annu. Rev. Immunol. 19:65-91, 2001.

 

Capitoli di libri

  • 1.         Iannacone M., F.V. Chisari and L.G. Guidotti. Protective and Pathogenic T Cell Responses to Virus Infections. Encyclopedia of Immunobiology. Edited by Michael J.H. Ratcliffe. Elsevier, Volume 4, pages 318-323, 2016.
  • 2.         Iannacone M., and L.G. Guidotti. HBV Immunopathogenesis. In: Hepatitis B Virus in human diseases. Edited by Fabien Zoulim and Yun-Fan Liaw, Springer Book, pages 79-93, 2016.

 

  • 3.         Iannacone M., and L.G. Guidotti. Mouse Models of Hepatitis B Virus Pathogenesis. Hepatitis B and Delta Viruses, Edited by Christoph Seeger and Stephen A. Locarnini, Cold Spring Harbor Perspectives in Medicine, doi: 10.1101/cshperspect.a021477, 2015.
  • 4.         Guidotti L.G. Animal models of hepatitis B and C. Encyclopedia of Medical Immunology. Editors I.R. Mackay and N.R. Rose, Springer. 2014, Vol. 1, pages 44-49, ISBN 978-0-387-84827-3.

English version

Short Narrative

Luca G. Guidotti (LGG) is an experimental pathologist of international renown. LGG spent many years as part of the TSRI faculty in La Jolla, California and he currently serves as Deputy Scientific Director of the largest private Research Institute in Italy, the IRCCS Ospedale San Raffaele (OSR) in Milan, Italy. Over the years, LGG has published his work in prestigious scientific journals such as Cell, Nature, Science, Nature Medicine, Journal of Clinical Investigation, Journal of Experimental Medicine and others and his research activities have been financed by the National Institute of Health (NIH) and the European Research Council (ERC). LGG has been a member of numerous Study Sections at the NIH and the ERC for the allocation of funds to biomedical research.

http://scholar.google.it/citations?user=qkFz9wYAAAAJ&hl=it

Current Positions

2017-present  Full Professor of General Pathology, Vita-Salute University, Milan, Italy

2013-present  Deputy Scientific Director, Ospedale San Raffaele (OSR), Milan, Italy.

2005-present  Head, Immunopathology Unit, OSR, Milan, Italy.

2005-present   Adjunct Professor, Department of Immunology & Microbial Sciences, The Scripps Research Institute (TSRI), La Jolla, California, USA.

Previous Positions

2012-2013       Chair, Division of Immunology, Transplantation and Infectious Diseases, OSR, Milan, Italy.

1999-2005       Associate Professor, Department of Immunology & Microbial Sciences, TSRI, La Jolla, California, USA.

1995-1999       Assistant Professor, Department of Molecular and Experimental Medicine, TSRI, La Jolla, California, USA.

1992-1995       Assistant Professor (Ricercatore), Department of General Pathology, University of Parma, Medical School, Parma, Italy.

1991-1994       Post-doctoral fellow, Department of Molecular and Experimental Medicine, TSRI, La Jolla, California, USA.

Major awarded grants, honors and memberships

2010-2016       Recipient, ERC Advanced Grant: “Imaging liver immunopathology by intravital microscopy (IVM).

2008-present  Member, Eureka Institute for Translational Medicine.

2004                            Honorary Member, Academic Society of Philosophy and Medicine, University of Parma.

2003                            Member, NIH/NIAID Advisory Panel for the Study of Liver Diseases.

2001                            Gold Medal for excellence in Antiviral Research, Schering Plough Japan, Tokyo, Japan.

1998-present Member, Organizing Committee, Annual International Meeting on Hepatitis B Viruses.

1996-2014      Recipient, NIH RO1 Grant AI40696: “Regulation of HBV replication by the immune system”.

 

Commissions of trust

2013-present   Reviewer and Member of the Panel, LS6 Immunity and Infection Panel, ERC Starting Grants (StG).

2012                            Reviewer, NIH Special Emphasis Panel ZRG1 IDM-B (03).

2011-2012       Reviewer, The Research Foundation Flanders (FWO), Brussels, Belgium, Postdoctoral Fellowships and Senior Investigator Grants.

2010                            Reviewer, Recovery act limited competition: NIH Directors’ opportunity for research in 5 thematic areas (RC4).

2009                              Chairman, European Congress of Immunology (ECI), Berlin, Germany.

2008-2010         Reviewer, BMRC & NMRC Singapore Grants.

2008                              Reviewer, NIH RFA-ZDK1-GRB-G “Hepatitis B Clinical Research Network” Review.

2007-2014         External Reviewer, ERC StG and Consolidator Grants, 2007, 2010, 2014 and 2017.

2002-2003         Reviewer, The Wellcome Trust, UK, Project Grants.

2002                Reviewer, RFP-NIH-NIAID “Drug Development for Opportunistic Infections: Hepatitis C” Study Section ZAI1-GPJ-A-C1.

2001                             Reviewer, NIH Special Study Section (ZRG MBC-2).

2000-2001         Reviewer, NIH Virology (VR) B, Study Section.

1998-2000         Reviewer, NIH General Medicine (GM) 2, Study Section.

 

Editorial Boards

2015-present     Current Opinion of Virology

 

Manuscript reviewing

1995-present   Reviewer for Cell, Nature, Nature Medicine, Science, Science Immunology, Proc. Nat’l Acad. Sci., USA, The Lancet, Journal of Experimental Medicine, Journal of Clinical Investigation, PloS Pathogens, American Journal of Pathology, Journal of Immunology, Journal of Virology, Virology, Journal of Infectious Diseases, Human Gene Therapy, Hepatology, Journal of Hepatology. 

 

Organization of scientific meetings

2017                            Co-Organizer of the international Nature Conference on “Regeneration” (http://www.nature.com/natureconferences/regen17/index.html), OSR, Milan, Italy.

1998                            Organizer of the international meeting: “The Molecular Biology of Hepatitis B Viruses”, University of California San Diego (UCSD), San Diego, CA.

 

Teaching activities

2008-2017           Adjunct Professor of General Pathology, Vita-Salute University, Medical School, Milan, Italy

 

Institutional activities

2010-present     Member, Institutional Animal Care and Use Committees (OSR-IACUC)

2013-present     Member, Financial Conflict of Interest Committee (OSR-FCOI)

2013-present     Member, OSR Ethics Committee (OSR-EC).

2013-present     Member, OSR Committee on Cooperative Research, Patents, and Licensing.

 

Professional Societies

Henry Kunkel Society, American Association of Immunology, American Society for Microbiology, Italian Society of Clinical Immunology and Allergology (SIICA)

 

Advisory Boards

2004-present     Co-founder and Member of the Board of Capitalife Inc., Reno, Nevada, USA.

2013-present     Member, Gilead Sciences “HBV CURE Advisory Board”, Foster City, CA, USA.

2015-present, Member and Deputy Spokesman, Research4life (http://www.research4life.it)

2017-present     Member, International Coalition to Eliminate Hepatitis B virus (ICE-HBV), Melbourne.

Il titolare del presente curriculum vitae, pubblicato online sul portale www.unisr.it, è garante in via esclusiva della correttezza e della veridicità dei dati e delle informazioni in esso riportate e del loro eventuale e puntuale aggiornamento. Egli è dunque il diretto ed unico responsabile dei contenuti indicati nei propri curricula.